Quality of life is predictive of relapse in schizophrenia

BMC Psychiatry

Mondher Toumi¹  Pascal Auquier²  Samuel Aballea³  Emeline Perthame³  Aurelie Millier³  Laurent Boyer² 

[1] Decision Sciences & Health Policy, Boulevard du 11 Novembre 1918, UCBL 1 - Chair of Market Access University Claude Bernard Lyon I, Villeurbanne, 69622, France;Aix-Marseille Univ, EA 3279 Research Unit, Marseille, 13284, France;Creativ-Ceutical France, rue du Faubourg Saint-Honoré, Paris, 75008, France

关键词: Recovery;    Functioning;    Compliance;    Relapse;    Quality of life;    Schizophrenia;   

Others  :  1124178
DOI  :  10.1186/1471-244X-13-15

 received in 2012-01-18, accepted in 2013-01-04,  发布年份 2013

【 摘 要 】

Background

The objective of this study was to evaluate whether quality of life (QoL), as measured by the SF36 and the Quality of Life Interview (QoLI), is predictive of relapse for patients with schizophrenia.

Methods

Using data from a multicenter cohort study conducted in France, Germany, and the United-Kingdom (EuroSC), we performed Cox proportional-hazards models to estimate the associations between QoL at baseline and the occurrence of relapse over a 24-month period, with adjustment for age; gender; positive, negative and general psychopathology PANSS factors; functioning (GAF); medication; side-effects; and compliance measures.

Results

Our sample consisted of 1,024 patients; 540 (53%) had at least one period of relapse, and 484 (47%) had no relapse. QoL levels were the most important features predicting relapse. We found that a higher level of QoL predicts a lower rate of relapse at 24 months: HR = 0.82 (0.74; 0.91), p < 0.001 for the SF36-Physical Composite Score; and HR = 0.88 (0.81; 0.96), p = 0.002 for the SF36-Mental Composite Score. These results were not confirmed using the QoLI: HR = 0.91 (0.81; 1.01), p = 0.083. To a lesser extent, older age, better functioning, and a higher compliance score also predict a lower rate of relapse at 24 months (HRs from 0.97 to 0.98; p < 0.05).

Conclusions

QoL, as assessed by the SF36, is an independent predictor of relapse at a 24-month follow-up in schizophrenia. This finding may have implications for future use of the QoL in psychiatry. Moreover, our findings may support the development and monitoring of complementary therapeutic approaches, such as ‘recovery-oriented’ combined with traditional mental health cares to prevent relapse.

【 授权许可】

   
2013 Boyer et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Ascher-Svanum H, Zhu B, Faries DE, Salkever D, Slade EP, Peng X, Conley RR: The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry 2011, 10:2.
• [2]Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Lieberman JA: Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999, 56:241-247.
• [3]Wiersma D, Nienhuis FJ, Slooff CJ, Giel R: Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. Schizophr Bull 1998, 24:75-85.
• [4]Awad AG, Voruganti LN: The burden of schizophrenia on caregivers: a review. Pharmacoeconomics 2008, 26:149-162.
• [5]Almond S, Knapp M, Francois C, Toumi M, Brugha T: Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 2004, 184:346-351.
• [6]Hong J, Windmeijer F, Novick D, Haro JM, Brown J: The cost of relapse in patients with schizophrenia in the European SOHO (Schizophrenia Outpatient Health Outcomes) study. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:835-841.
• [7]Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P, Jeste DV: Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004, 161:692-699.
• [8]Ayuso-Gutierrez JL, Del Rio Vega JM: Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res 1997, 28:199-206.
• [9]Lipkovich I, Deberdt W, Csernansky JG, Buckley P, Peuskens J, Kollack-Walker S, Zhang Y, Liu-Seifert H, Houston JP: Predictors of risk for relapse in patients with schizophrenia or schizoaffective disorder during olanzapine drug therapy. J Psychiatr Res 2007, 41:305-310.
• [10]Van Os J, Kapur S: Schizophrenia. Lancet 2009, 374:635-645.
• [11]Allardyce J, Boydell J: Review: the wider social environment and schizophrenia. Schizophr Bull 2006, 32:592-598.
• [12]Power M, Harper A, Bullinger M: The World Health Organization WHOQOL-100: tests of the universality of Quality of Life in 15 different cultural groups worldwide. Health Psychol 1999, 18:495-505.
• [13]Kalantar-Zadeh K, Kopple JD, Block G, Humphreys MH: Association among SF36 quality of life measures and nutrition, hospitalization, and mortality in hemodialysis. J Am Soc Nephrol 2001, 12:2797-2806.
• [14]Parshall MB, Mapel DW, Rice L, Williams A, O’Reilly J: Predictive validity of short-form health survey [36 items] scales for chronic obstructive pulmonary disease exacerbation. Heart Lung 2008, 37:356-365.
• [15]Sehlen S, Lenk M, Hollenhorst H, Schymura B, Aydemir U, Herschbach P, Duhmke E: Quality of life (QoL) as predictive mediator variable for survival in patients with intracerebral neoplasma during radiotherapy. Onkologie 2003, 26:38-43.
• [16]Sprenkle MD, Niewoehner DE, Nelson DB, Nichol KL: The Veterans Short Form 36 questionnaire is predictive of mortality and health-care utilization in a population of veterans with a self-reported diagnosis of asthma or COPD. Chest 2004, 126:81-89.
• [17]Yeo W, Mo FK, Koh J, Chan AT, Leung T, Hui P, Chan L, Tang A, Lee JJ, Mok TS, et al.: Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. Ann Oncol 2006, 17:1083-1089.
• [18]Chen EY, Hui CL, Dunn EL, Miao MY, Yeung WS, Wong CK, Chan WF, Tang WN: A prospective 3-year longitudinal study of cognitive predictors of relapse in first-episode schizophrenic patients. Schizophr Res 2005, 77:99-104.
• [19]Weiden PJ, Olfson M: Cost of relapse in schizophrenia. Schizophr Bull 1995, 21:419-429.
• [20]Bebbington PE, Angermeyer M, Azorin JM, Brugha T, Kilian R, Johnson S, Toumi M, Kornfeld A: The European Schizophrenia Cohort (EuroSC): a naturalistic prognostic and economic study. Soc Psychiatry Psychiatr Epidemiol 2005, 40:707-717.
• [21]Diagnostic and Statistical Manual of Mental Disorders. 4th edition. American Psychiatric Association, Washington, DC; 1994.
• [22]Kay SR, Opler LA, Fiszbein A: Significance of positive and negative syndromes in chronic schizophrenia. Br J Psychiatry 1986, 149:439-448.
• [23]Endicott J, Spitzer RL, Fleiss JL, Cohen J: The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976, 33:766-771.
• [24]Simpson S, Angus R: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970, (212):11-19.
• [25]Barnes TR: A rating scale for drug-induced akathisia. Br J Psychiatry 1989, 154:672-676.
• [26]Lane RD, Glazer WM, Hansen TE, Berman WH, Kramer SI: Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale. J Nerv Ment Dis 1985, 173:353-357.
• [27]Weiden P, Rapkin B, Mott T, Zygmunt A, Goldman D, Horvitz-Lennon M, Frances A: Rating of medication influences (ROMI) scale in schizophrenia. Schizophr Bull 1994, 20:297-310.
• [28]Ware JE Jr, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30:473-483.
• [29]Lehman AF: A quality of life interview for the chronically mentally ill. Eval Program Plann 1988, 11(1):51-62.
• [30]Lader M: What is relapse in schizophrenia? Int Clin Psychopharmacol 1995, 9(Suppl 5):5-9.
• [31]Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM: Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003, 160:1209-1222.
• [32]Cramer JA, Rosenheck R, Xu W, Thomas J, Henderson W, Charney DS: Quality of life in schizophrenia: a comparison of instruments. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Schizophr Bull 2000, 26:659-666.
• [33]Reine G, Simeoni MC, Auquier P, Loundou A, Aghababian V, Lancon C: Assessing health-related quality of life in patients suffering from schizophrenia: a comparison of instruments. Eur Psychiatry 2005, 20:510-519.
• [34]De Hert M, Cohen D, Bobes J, Cetkovich-Bakmas M, Leucht S, Ndetei DM, Newcomer JW, Uwakwe R, Asai I, Moller HJ, et al.: Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry 2011, 10:138-151.
• [35]Millar H: Management of physical health in schizophrenia: a stepping stone to treatment success. Eur Neuropsychopharmacol 2008, 18(Suppl 2):S121-S128.
• [36]Chabungbam G, Avasthi A, Sharan P: Sociodemographic and clinical factors associated with relapse in schizophrenia. Psychiatry Clin Neurosci 2007, 61:587-593.
• [37]Roe D, Mashiach-Eizenberg M, Lysaker PH: The relation between objective and subjective domains of recovery among persons with schizophrenia-related disorders. Schizophr Res 2011, 131:133-138.
• [38]Silverstein SM, Bellack AS: A scientific agenda for the concept of recovery as it applies to schizophrenia. Clin Psychol Rev 2008, 28:1108-1124.
• [39]Boyer L, Richieri R, Faget C, Padovani R, Vaillant F, Mundler O, Lancon C, Auquier P, Guedj E: Functional involvement of superior temporal sulcus in quality of life of patients with schizophrenia. Psychiatry Res 2012, 202(2):155-160.
• [40]Lysaker PH, Erickson MA, Buck B, Buck KD, Olesek K, Grant ML, Salvatore G, Popolo R, Dimaggio G: Metacognition and social function in schizophrenia: associations over a period of five months. Cogn Neuropsychiatry 2011, 16:241-255.
• [41]Lysaker PH, Buck KD, Carcione A, Procacci M, Salvatore G, Nicolò G, Dimaggio G: Addressing metacognitive capacity for self reflection in the psychotherapy for schizophrenia: a conceptual model of the key tasks and processes. Psychol Psychother 2010. Epub ahead of print
• [42]Falloon IR: Relapse: a reappraisal of assessment of outcome in schizophrenia. Schizophr Bull 1984, 10:293-299.
• [43]Caseiro O, Pérez-Iglesias R, Mata I, Martínez-Garcia O, Pelayo-Terán JM, Tabares-Seisdedos R, Ortiz-García de la Foz V, Vázquez-Barquero JL, Crespo-Facorro B: Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study. J Psychiatr Res 2012, 46(8):1099-1105.
• [44]Fleischhacker WW, Rabinowitz J, Kemmler G, Eerdekens M, Mehnert A: Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year. Br J Psychiatry 2005, 187:131-136.
• [45]Papaioannou D, Brazier J, Parry G: How valid and responsive are generic health status measures, such as EQ-5D and SF-36, in schizophrenia? A systematic review. Value Health 2011, 14:907-920.
• [46]Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, Docherty JP: The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 2009, 70(Suppl 4):1-46. quiz 47–48
• [47]Awad AG, Voruganti LN: Intervention research in psychosis: issues related to the assessment of quality of life. Schizophr Bull 2000, 26:557-564.
• [48]Gilbody SM, House AO, Sheldon TA: Psychiatrists in the UK do not use outcomes measures. National survey. Br J Psychiatry 2002, 180:101-103.
• [49]Greenhalgh J, Long AF, Flynn R: The use of patient reported outcome measures in routine clinical practice: lack of impact or lack of theory? Soc Sci Med 2005, 60:833-843.
• [50]Boyer L, Auquier P: The lack of impact of quality-of-life measures in schizophrenia: a shared responsibility? Pharmacoeconomics 2012, 30(6):531-2.